These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 28251900)

  • 1. Immunotherapy-related skin toxicity: bullous pemphigoid in a lung adenocarcinoma patient treated with the anti-PDL1 antibody atezolizumab.
    Russo I; Sacco G; Frega S; Polo V; Pasello G; Alaibac M
    Eur J Dermatol; 2017 Apr; 27(2):205-208. PubMed ID: 28251900
    [No Abstract]   [Full Text] [Related]  

  • 2. A case of atezolizumab-induced photodistributed bullous pemphigoid.
    Leavitt E; Holland V
    Dermatol Ther; 2019 Jul; 32(4):e12924. PubMed ID: 30977954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bullous pemphigoid in elderly woman affected by non-small cell lung cancer treated with pembrolizumab: A case report and review of literature.
    Cosimati A; Rossi L; Didona D; Forcella C; Didona B
    J Oncol Pharm Pract; 2021 Apr; 27(3):727-733. PubMed ID: 32772795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erlotinib-induced bullous pemphigoid.
    Stingeni L; Bianchi L; Minotti V; Lisi P
    J Am Acad Dermatol; 2012 Nov; 67(5):e199-201. PubMed ID: 23062911
    [No Abstract]   [Full Text] [Related]  

  • 5. Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma.
    Mochel MC; Ming ME; Imadojemu S; Gangadhar TC; Schuchter LM; Elenitsas R; Payne AS; Chu EY
    J Cutan Pathol; 2016 Sep; 43(9):787-91. PubMed ID: 27161449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune mediated colitis caused by lung cancer treatment with atezolizumab.
    González Vázquez S; de la Riva Onandía S; Echeveste JI; Muñoz Navas M
    Rev Esp Enferm Dig; 2017 Dec; 109(12):863-864. PubMed ID: 29019253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperprogression after first dose of immunotherapy in a patient with radioresistant metastasis from nonsmall cell lung cancer.
    Bosch-Barrera J; Oliva E; Sais E; Vásquez CA; Roselló A; Menéndez JA
    Anticancer Drugs; 2019 Nov; 30(10):1067-1070. PubMed ID: 31567311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bullous dermatoses secondary to anti-PD-L1 agents: a case report and review of the literature.
    Kosche C; Owen JL; Sadowsky LM; Choi JN
    Dermatol Online J; 2019 Oct; 25(10):. PubMed ID: 31735006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges.
    Giroux Leprieur E; Dumenil C; Julie C; Giraud V; Dumoulin J; Labrune S; Chinet T
    Eur J Cancer; 2017 Jun; 78():16-23. PubMed ID: 28407528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe bullous pemphigoid in a metastatic lung cancer patient treated with pembrolizumab.
    Adachi E; Honda T; Nonoyama S; Irie H; Yamamura K; Otsuka A; Kabashima K
    J Dermatol; 2019 Jul; 46(7):e232-e233. PubMed ID: 30758879
    [No Abstract]   [Full Text] [Related]  

  • 11. Development of bullous pemphigoid during treatment of psoriasis with adalimumab.
    Stausbøl-Grøn B; Deleuran M; Sommer Hansen E; Kragballe K
    Clin Exp Dermatol; 2009 Oct; 34(7):e285-6. PubMed ID: 19438555
    [No Abstract]   [Full Text] [Related]  

  • 12. Does adalimumab cause bullous pemphigoid?
    Toosi S; Bystryn JC
    Clin Exp Dermatol; 2010 Oct; 35(7):795. PubMed ID: 20831605
    [No Abstract]   [Full Text] [Related]  

  • 13. Development of Halo Nevi in a Lung Cancer Patient: A Novel Immune-Related Cutaneous Event from Atezolizumab.
    Birnbaum MR; Ma MW; Casey MA; Amin BD; Jacobson M; Cheng H; McLellan BN
    J Drugs Dermatol; 2017 Oct; 16(10):1047-1049. PubMed ID: 29036261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bullous pemphigoid after chemotherapy for choriocarcinoma.
    Amer MH; Akhtar M; Mackey DM; Butler PG
    Int J Dermatol; 1982; 21(1):32-5. PubMed ID: 7037665
    [No Abstract]   [Full Text] [Related]  

  • 15. Efalizumab-induced bullous pemphigoid.
    Duong TA; Buffard V; André C; Ortonne N; Revuz J; Bagot M; Roujeau JC
    J Am Acad Dermatol; 2010 Jan; 62(1):161-162. PubMed ID: 20082902
    [No Abstract]   [Full Text] [Related]  

  • 16. [Bullous pemphigoid induced by cancer immunotherapy].
    Giroud S; Chiticariu-Durr E
    Rev Med Suisse; 2020 Apr; 16(688):624-628. PubMed ID: 32239835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma.
    Parakh S; Nguyen R; Opie JM; Andrews MC
    Australas J Dermatol; 2017 Aug; 58(3):e109-e112. PubMed ID: 27170423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: A case report.
    Uenami T; Hosono Y; Ishijima M; Kanazu M; Akazawa Y; Yano Y; Mori M; Yamaguchi T; Yokota S
    Lung Cancer; 2017 Jul; 109():42-44. PubMed ID: 28577948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case Report: A Presentation of Early-Onset Immune-Mediated Bullous Pemphigoid in a Patient with Urothelial Cancer.
    Sabaté Ortega J; Fort Culillas R; Escoda Garcia M; Vásquez-Dongo CA; Sala González N
    Curr Oncol; 2023 Aug; 30(9):7802-7809. PubMed ID: 37754481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autoimmune bullous skin diseases occurring under anti-tumor necrosis factor therapy: two case reports.
    Boussemart L; Jacobelli S; Batteux F; Goulvestre C; Grange P; Carlotti A; Morini JP; Gorin I; Ziza JM; Avril MF; Dupin N
    Dermatology; 2010; 221(3):201-5. PubMed ID: 20720390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.